Skip to main content

$0.012 (0%)

High

$0.01

Low

$0.01

Trades

21

Turnover

$70,215

Volume

5,851,219
30 June 2023 at 4:10pm
Register to track OSL and receive email alerts.
Subject
OSL Ann: Notification regarding unquoted securities - OSL

OSL Ann: Change of Director's Interest Notice - Brian Leedman

OSL Ann: Change of Director's Interest Notice - Ricky Sharma

OSL Ann: Change of Director's Interest Notice - Otto Buttula

OSL Ann: Notification regarding unquoted securities - OSL

OSL Ann: Results of the OncoSil 2022 Annual General Meeting

OSL Ann: 2022 AGM CEO Presentation

OSL Ann: Final Director's Interest Notice

OSL Ann: Resignation of Director - Dr Martin Cross

OSL Ann: OncoSil Receives $832k R&D Tax Incentive

OSL Ann: OncoSil to Present at South-West Connect ASX Showcase

OSL Ann: Proposed issue of securities - OSL

OSL Ann: Notice of Annual General Meeting/Proxy Form

OSL Ann: Initial Director's Interest Notice

OSL Ann: Brian Leedman appointed to the Board of OncoSil

OSL Ann: Appendix 4G and Corporate Governance Statement

OSL Ann: Appendix 4E Announcement

OSL Ann: Appendix 4E and Annual Report

OSL Ann: Investor Presentation

OSL Ann: Investor Presentation Webinar Wednesday 3rd August 2022

OSL Ann: Monthly Activities/Appendix 4C Cash Flow Report

OSL Ann: Patient treated in Spain proceeds to successful resection

OSL Ann: Bupa UK Approves Reimbursement for OncoSil in the UK

OSL Ann: FY 2023 Strategic Update

OSL Ann: OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC

OSL Ann: Application for quotation of securities - OSL

OSL Ann: Cleansing Notice

OSL Ann: Change of Director's Interest Notice - Otto Buttula

OSL Ann: Change of Director's Interest Notice - Nigel Lange

OSL Ann: Change of Director's Interest Notice - Martin Cross

OSL Ann: Application for quotation of securities - OSL

OSL Ann: Entitlement Offer Results and Shortfall Notification

OSL Ann: Trading Halt

OSL Ann: Letter To Ineligible Shareholders

OSL Ann: OncoSil Entitlement Offer Booklet

OSL Ann: Application for quotation of securities - OSL

OSL Ann: Cleansing Notice

OSL Ann: Clarification Of Non-Renouncable Entitlement Offer Details

OSL Ann: Proposed issue of securities - OSL

OSL Ann: Cleansing Notice

OSL Ann: Investor Presentation

OSL Ann: OncoSil Launches $10m Capital Raising

OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

OSL Ann: OncoSil Signs Commercial Agreement With Hospital In Spain

OSL Ann: Trading Halt

OSL Ann: First Commerical Pancreas Treatment In Spain

OSL Ann: Fully-Funded Trial Approved In Germany

OSL Ann: Half Yearly Report Results

OSL Ann: Half Yearly Report and Accounts

OSL Ann: OncoSil approved for Innovation Funding (NUB) in Germany

Register to track OSL and receive email alerts.

Similar Companies

ADO
BPH
CTE
GSS
GTG
MEM
PAL
PIQ